Literature DB >> 31894096

Therapeutic targeting of mutated p53 in acute lymphoblastic leukemia.

Frank N van Leeuwen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31894096      PMCID： PMC6939537          DOI： 10.3324/haematol.2019.234872

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  9 in total

Review 1.  TP53 Mutations in Hypodiploid Acute Lymphoblastic Leukemia.

Authors:  Evan Q Comeaux; Charles G Mullighan
Journal:  Cold Spring Harb Perspect Med       Date:  2017-03-01       Impact factor: 6.915

2.  Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia.

Authors:  Jana Hof; Stefanie Krentz; Claudia van Schewick; Gabriele Körner; Shabnam Shalapour; Peter Rhein; Leonid Karawajew; Wolf-Dieter Ludwig; Karl Seeger; Günter Henze; Arend von Stackelberg; Christian Hagemeier; Cornelia Eckert; Renate Kirschner-Schwabe
Journal:  J Clin Oncol       Date:  2011-07-11       Impact factor: 44.544

3.  The antioxidant function of the p53 tumor suppressor.

Authors:  Anna A Sablina; Andrei V Budanov; Galina V Ilyinskaya; Larissa S Agapova; Julia E Kravchenko; Peter M Chumakov
Journal:  Nat Med       Date:  2005-11-13       Impact factor: 53.440

Review 4.  p53 in survival, death and metabolic health: a lifeguard with a licence to kill.

Authors:  Flore Kruiswijk; Christiaan F Labuschagne; Karen H Vousden
Journal:  Nat Rev Mol Cell Biol       Date:  2015-07       Impact factor: 94.444

5.  Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.

Authors:  Vladimir J N Bykov; Natalia Issaeva; Alexandre Shilov; Monica Hultcrantz; Elena Pugacheva; Peter Chumakov; Jan Bergman; Klas G Wiman; Galina Selivanova
Journal:  Nat Med       Date:  2002-03       Impact factor: 53.440

6.  The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases.

Authors:  A Stengel; W Kern; T Haferlach; M Meggendorfer; A Fasan; C Haferlach
Journal:  Leukemia       Date:  2016-09-29       Impact factor: 11.528

7.  PRIMA-1 reactivates mutant p53 by covalent binding to the core domain.

Authors:  Jeremy M R Lambert; Petr Gorzov; Dimitry B Veprintsev; Maja Söderqvist; Dan Segerbäck; Jan Bergman; Alan R Fersht; Pierre Hainaut; Klas G Wiman; Vladimir J N Bykov
Journal:  Cancer Cell       Date:  2009-05-05       Impact factor: 31.743

Review 8.  Clinical Overview of MDM2/X-Targeted Therapies.

Authors:  Andrew Burgess; Kee Ming Chia; Sue Haupt; David Thomas; Ygal Haupt; Elgene Lim
Journal:  Front Oncol       Date:  2016-01-27       Impact factor: 6.244

9.  APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase.

Authors:  Xiaoxiao Peng; Mei-Qiong-Zi Zhang; Francesca Conserva; Gihan Hosny; Galina Selivanova; Vladimir Jn Bykov; Elias Sj Arnér; Klas G Wiman
Journal:  Cell Death Dis       Date:  2017-04-13       Impact factor: 8.469
  9 in total
  1 in total

1.  Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells.

Authors:  Sophia Ceder; Sofi E Eriksson; Ying Yu Liang; Emarndeena H Cheteh; Si Min Zhang; Kenji M Fujihara; Julie Bianchi; Vladimir J N Bykov; Lars Abrahmsen; Nicholas J Clemons; Pär Nordlund; Sean G Rudd; Klas G Wiman
Journal:  Cell Death Dis       Date:  2021-07-15       Impact factor: 9.685
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.